Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Novo Nordisk A/S Key Target Audience Market Players Investors End-users Government Authorities Consulting and Research Firm Venture capitalists Value-Added Resellers (VARs) Recent Development In January 2023, Semaglutide (Wegovy- Novo Nordisk) has been licensed by the US Food and Drug Administration for the treatment of obesity in pediatric patients aged 12 and above
Co-pays as low as $50
Standard household refrigerators maintain appropriate temperatures with minimal operating cost
The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs
Treatment for vitamin B12 deficiency is often with injections
US$ 26.28
US$ 29.89
US$ 27.81
US$ 28.51
